Liraglutide Decreases Liver Fat Content and Serum Fibroblast Growth Factor 21 Levels in Newly Diagnosed Overweight Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease

High baseline FGF21 levels are associated with poor glucose-lowering efficacy of exenatide in patients with type 2 diabetes

(2021) Kun Yang et al.   ACTA DIABETOLOGICA

Effects of Glucagon-Like Peptide-1 Analogue and Fibroblast Growth Factor 21 Combination on the Atherosclerosis-Related Process in a Type 2 Diabetes Mouse Model

(2021) Jin Hee Kim et al.   Endocrinology and Metabolism

Hepatic fibroblast growth factor 21 is involved in mediating functions of liraglutide in mice with dietary challenge

(2021) Dinghui Liu et al.   HEPATOLOGY

Current understanding and controversies on the clinical implications of fibroblast growth factor 21

(2020) Yasaman Badakhshi et al.   CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES

Liver-derived fibroblast growth factor 21 mediates effects of glucagon-like peptide-1 in attenuating hepatic glucose output

(2019) Junling Liu et al.   EBioMedicine

Plasma Fibroblast Growth Factor 21 is Associated with Severity of Nonalcoholic Steatohepatitis in Patients with Obesity and Type 2 Diabetes

(2019) Diana Barb et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Fibroblast growth factor 21 for non-alcoholic steatohepatitis

(2018) Vincent W S Wong et al.   LANCET

Fatty liver and FGF21 physiology

(2017) Eleftheria Maratos-Flier   EXPERIMENTAL CELL RESEARCH

Current and future pharmacological therapies for NAFLD/NASH

(2017) Yoshio Sumida et al.   JOURNAL OF GASTROENTEROLOGY

Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy

(2016) A. Dutour et al.   DIABETES OBESITY & METABOLISM

Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial

(2016) Mark M. Smits et al.   DIABETOLOGIA

Diet polyphenol curcumin stimulates hepatic Fgf21 production and restores its sensitivity in high fat diet fed male mice

(2016) Kejing Zeng et al.   ENDOCRINOLOGY

Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes

(2016) Zobair M. Younossi et al.   HEPATOLOGY

Effect of liraglutide therapy on liver fat content in patients with inadequately controlled type 2 diabetes. The Lira-NAFLD study

(2016) Jean-Michel Petit et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study

(2016) Matthew James Armstrong et al.   LANCET

Association of noninvasive quantitative decline in liver fat content on MRI with histologic response in nonalcoholic steatohepatitis

(2016) Janki Patel et al.   Therapeutic Advances in Gastroenterology

Effects of Insulin Glargine and Liraglutide Therapy on Liver Fat as Measured by Magnetic Resonance in Patients With Type 2 Diabetes: A Randomized Trial

(2015) An Tang et al.   DIABETES CARE

Nonalcoholic fatty liver disease: A precursor of the metabolic syndrome

(2015) Amedeo Lonardo et al.   DIGESTIVE AND LIVER DISEASE

Circulating FGF21 Is Liver Derived and Enhances Glucose Uptake During Refeeding and Overfeeding

(2014) K. R. Markan et al.   DIABETES

Benefits of exenatide on obesity and non-alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes

(2014) Ning Shao et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

Standards of Medical Care in Diabetes--2013

(2012)   DIABETES CARE

GLP-1 Receptor Activation Indirectly Reduces Hepatic Lipid Accumulation But Does Not Attenuate Development of Atherosclerosis in Diabetic MaleApoE−/−Mice

(2012) Naim Panjwani et al.   ENDOCRINOLOGY

High serum level of fibroblast growth factor 21 is an independent predictor of non-alcoholic fatty liver disease: A 3-year prospective study in China

(2012) Huating Li et al.   JOURNAL OF HEPATOLOGY

Serum FGF21 levels are increased in newly diagnosed type 2 diabetes with nonalcoholic fatty liver disease and associated with hsCRP levels independently

(2011) Xuesong Li et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial

(2011) S. L. Samson et al.   DIABETOLOGIA

Increased serum FGF21 levels in patients with nonalcoholic fatty liver disease

(2010) Yusuf Yilmaz et al.   EUROPEAN JOURNAL OF CLINICAL INVESTIGATION

Increased Fibroblast Growth Factor 21 in Obesity and Nonalcoholic Fatty Liver Disease

(2010) Jody Dushay et al.   GASTROENTEROLOGY

Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway

(2010) Nitika Arora Gupta et al.   HEPATOLOGY

Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase

(2010) Shani Ben-Shlomo et al.   JOURNAL OF HEPATOLOGY

Homeostasis Model Assessment (HOMA) as Surrogate Insulinization Criteria in Patients With Type 2 Diabetes

(2009) Valmore Bermúdez et al.   AMERICAN JOURNAL OF THERAPEUTICS

Circulating Fibroblast Growth Factor-21 Is Elevated in Impaired Glucose Tolerance and Type 2 Diabetes and Correlates With Muscle and Hepatic Insulin Resistance

(2009) A. O. Chavez et al.   DIABETES CARE

Serum FGF21 Levels Are Increased in Obesity and Are Independently Associated With the Metabolic Syndrome in Humans

(2008) X. Zhang et al.   DIABETES

Adipose Fibroblast Growth Factor 21 Is Up-Regulated by Peroxisome Proliferator-Activated Receptor   and Altered Metabolic States

(2008) E. S. Muise et al.   MOLECULAR PHARMACOLOGY